UNSPSC 51372128: Oxycodone terephthalate

This classification denotes an opioid receptor agonist and opioid with the molecular structure 2C18H21NO4.C8H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, M04XWV43UF chemically known as 4,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one 1,4-benzenedicarboxylate (2:1 salt), but more commonly known as oxycodone terephthalate, which bears US NIH Compound Identifier 5464088.

UNSPSC 51372128 Oxycodone terephthalate is a Commodity code that, based on recent state and local solicitations, encompasses pharmaceutical products and related supply-chain arrangements for government health and community programs. The code shows limited direct matching to the nominal oxycodone product — recent opportunities instead reflect state and local procurement of broader pharmaceutical categories, including naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesale channels. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). These jurisdictions solicit pharmaceutical supply through a mix of competitive bidding (IFB), exploratory information requests (RFI), and formal request-for-proposal (RFP) mechanisms.

Recent activity appears concentrated in the South and Upper Midwest. Seminole County, Florida issued an IFB in July 2026 (due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, requiring electronic bid submission with drug-free workplace and E-Verify certification. Texas HHS Commission posted an RFI in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to explore direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with contract effectiveness July 1, 2026, requiring cGMP and Drug Supply Chain Security Act compliance and comprehensive insurance coverage including $5 million commercial general liability per occurrence.